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Primary Hyperparathyroidism: Changing Patterns in
Presentation and Treatment Decisions in the Eighties
D. Sudhaker Rao, MBBS*
Table I
Clinical Manifestations of Hypercalcemia*

A simple blood test, done because it is so cheap rather
than because it is medically necessary, is leading to
the diagnosis and treatment of people who didn't
know they were sick and (often after evaluation and
treatment), neither the doctor nor the patient know
whether the patients are better off (1).
In the beginning primary hyperparathyroidism (PHPT) was
a disease of stones and bones, abdominal moans and groans
with psychic overtones, and now "As mild primary hyperparathyroidism 'emerged' in the 60s and 70s, the pendulum
swung away from reflexive surgical treatment....What is
clear is that there is much more to be learned about this 'new
disease'; meanwhile, the cauldron of controversy will
remain well stirred" (2).
More than a half century has elapsed since a parathyroid
adenoma was successfully removed from a patient suffering
from osteitis fibrosa cystica (3). From 1926 to approximately
1960, PHPT was dominated by the usual manifestations that
have become characteristic of this disease. With today's
routine measurement of serum calcium, PHPT is now one
of the most common endocrine disorders; current estimates
indicate a prevalence of PHPT between 0 . 1 % and 0.5%
(4,5), with a female preponderance. Because of early
recognition and diagnosis, the clinical manifestations of
PHPT have changed significantly through the years, with the
majority of today's patients being asymptomatic (6-8). As
mild asymptomatic PHPT emerged in the 70s, the initial
conviction that every patient ought to be treated with
surgery has come into question (9,10), and it is therefore
necessary to reexamine whether all patients with PHPT
should be treated with surgical or medical management.
Already the enthusiasm for early surgery has waned, but the
controversy regarding treatment remains unsettled (2,11),

Skeletal

Arthritis
Chondrocalcinosis

Renal

Polyuria
Nephrolithiasis
Nephrocalcinosis
Renal insufficiency

Gastrointestinal

Polydipsia
Anorexia
Nausea and vomiting
Constipation
Pancreatitis

Neuropsychiatric

Memory impairment
Headaches and lethargy
Seizures and coma

Cardiovascular

Arrhythmias
Short QTc interval on EKG
Hypertension

Ocular and skin

Corneal calcification
Soft tissue calcification
Pruritus and "irritable" eyes

Nonspecific

Weakness and tiredness
Fatigue
Arthralgia

*Not necessarily those of underlying disease;
information modified from D. S. Rao (21)

by 1976 (Figure), but asymptomatic PHPT has steadily
increased since that time. Consequently, skeletal symptoms
as the presenting feature of PHPT have not been seen since
1980 at Henry Ford Hospital, although nephrolithiasis
continues to be present in a small number of patients (Rao,
unpublished data, 1985, and Figure). Interestingly, the
frequency of hypertension among patients with PHPT has
remained stable despite a decline in every other manifestation of this disease. Contrary to previous reports (8,20),
hypertension in these individuals is probably unrelated to
hypercalcemia or excess parathyroid hormone secretion.
Furthermore, the presentation of the disease is milder now,
and in most patients the serum calcium level rarely exceeds
11.5 mg/dL; however, it is not currently known whether any

Spectrum of Clinical Manifestations
Although PHPT is a disease of protean manifestations, in
patients with this disease in the past, skeletal and renal
complications accounted for more than 8 0 % to 9 0 % of the
presenting features (7,8,11-19), with gastrointestinal symptoms at a distant third. Even these modes of presentation
have declined over the past two decades and continue to
decline (Figure, Table I), The proportion of patients with
bone disease or kidney stones had decreased precipitously
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Figure
Changing pattern of presentation of primary hyperparathyroidism: total of 1,966
patients f r o m 11 reporfed series between
1948 and 1980 (7,8,11-19) and 58 patients
f r o m Henry Ford Hospital between 1980
and 1983 (presented as 1983). Only t w o
major manifestations of PHPT are used to
construct the curves. A.Sx.: asymptomatic.
Time scales are not at equal intervals.

significant morbidity is associated with this degree of
hypercalcemia.

duration still remains the single best laboratory test for
confirming the diagnosis of PHPT. Based on data from over
300 patients with this disease, clinically useful criteria for
the diagnosis of PHPT are summarized in Table II. With the
availability of immunoassays for parathyroid hormone (PTH)
and nephrogenous cyclic adenosine monophosphate
(NcAMP), a more direct confirmation of the diagnosis of
PHPT is possible. The immunologic heterogeneity of PTH
in the blood and the finding of elevated NcAMP in patients
with known malignancy have complicated the interpretation
of these results. Each physician should therefore be familiar
with the sensitivity and specificity of these tests (Table III).
Various diagnostic possibilities based on PTH and NcAMP
values in hypercalcemic patients are presented in Table IV
(22), and along with the previously mentioned criteria (Table
III), it should be relatively simple to confirm a diagnosis of
PHPT in most hypercalcemic patients.

The least understood manifestations of PHPT are the
neuromuscular and psychiatric symptoms. In general, the
frequency and severity of these symptoms correlate with the
degree of hypercalcemia and tend to decrease with the
normalization of serum calcium. Other less frequent manifestations of PHPT are summarized in Table I (21), and
clinical features are related to serum calcium level and not
to the causes of hypercalcemia.

Laboratory Investigations and Diagnostic
Considerations
Despite recent advances in understanding the pathophysiology of altered mineral metabolism, hypercalcemia of long
Table 11
Clinical Criteria for Diagnosis of PHPT
Major criteria

Minor criteria

Table lli
Specificity of Tests in Diagnosis of PHPT

Stable hypercalcemia (less than 12 mg/dL)
Long duration (more than one year)
Minimal fluctuations (less than 1 mg/dL)
Presence of target organ effects*

Measurement

Hypophosphatemia (less than 2.5 mg/dL)
Hyperchloremic acidosis (serum chloride more than
106 mEq/L)
Increased chloride/phosphate ratio (more than 35)
Relative hypocalciuriat

Number Positive

Percent Positive

Immunoreactive PTH

58 (71)*

82%

NcAMPt

64 (71)*

90%

TmP/GFRt

69 (71)*

97%

24-hour urine calcium

37 (61)

61%

*Parentheses indicate total number of patients tested simultaneously

•Subperiosteal bone resorption, "salt and pepper" skull, osteopenia or
osteoporosis, " b r o w n " tumors or bone fractures, and nephrolithiasis or
nephrocalcinosis

'Nephrogenous cyclic AMP represents biologic expression of endogenously secreted PTH and appears to be more sensitive than measurement of serum PTH in diagnosis of PHPT. Similarly, tubular maximum
for phosphate reabsorption (TmP/GER) also reflects endogenous PTH
secretion, although TmP/GER may be influenced by serum calcium
level independent of PTH secretion (22).

tLower urinary calcium excretion than would be expected for level of
serum calcium since PTH enhances renal tubular reabsorption of
calcium
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Table IV
Diagnostic Possibilities Based on PTH and N c A M P Values in Patients w i t h
Hypercalcemia*
Immunoreactive
Parathyroid Hormone

Nephrogenous
Cyclic AMP

Diagnostic
Consideration

Increased

Increased or normal

Primary or ectopic
hyperparathyroidism

Normal

Increased

Humoral hypercalcemia of
malignancy
Primary hyperparathyroidism

Decreased

Decreased

Non-PTH mediated hypercalcemia
Sarcoidosis
Milk-alkali syndrome
Calciferol poisoning

*Modified from M. Kleerekoper (22)

involvement. The extent of surgery must be individualized,
and selective parathyroidectomy is recommended for most
patients (23). Routine subtotal parathyroidectomy (ie, removal of three and one half of the remaining fourth gland)
is to be discouraged except in a select group of patients with
PHPT (23). The removal ofa single enlarged gland is curative
in over 8 0 % of patients with PHPT, with the remaining 2 0 %
requiring subtotal parathyroidectomy. The risk of recurrent
hyperparathyroidism or permanent postoperative hypoparathyroidism is approximately 5%.

Differential Diagnosis
In general, every patient with hypercalcemia should be
examined thoroughly for an occult malignancy or for a
nonparathyroid cause for hypercalcemia. However, experience suggests that in most patients the diseases that cause
hypercalcemia are obvious by history or physical examination, and further testing for an occult malignancy is usually
nonrevealing; this is true for the associated cancers or the
benign endocrine or nonendocrine tumors known to produce hypercalcemia. Certain general principles are helpful
in predicting the presence of PHPT in a hypercalcemic
patient. These guidelines include the following: 1) accidental
discovery of hypercalcemia is almost always due to underlying PHPT and rarely to multiple myeloma or sarcoidosis;
2) presence of nephrolithiasis in a patient with hypercalcemia is highly suggestive of PHPT; 3) when two diseases
known to produce hypercalcemia coexist (eg, PHPT and
malignancy, PHPT and hyperthyroidism, PHPT and sarcoidosis), only one or the other condition is responsible for the
hypercalcemia and not both; and 4) if one of the two
diseases is PHPT, it is the PHPT that causes hypercalcemia
and not the other condition (Rao, unpublished data, 1985).

Management of patients with asymptomatic PHPT is most
controversial (9-11). As parathyroidectomy is curative in
most patients, some claim that it is best to operate on every
patient as soon as the diagnosis is firmly established (14).
The most common reasons for this approach include the
high cost of following these patients indefinitely and the
difficulty in supervising patients for any length of time.
Although these presumptions may be true, the age group of
patients with PHPT is such that most would be followed
anyway for an unrelated medical condition. Furthermore,
serum calcium should be measured only twice a year since
hypercalcemia remains stable for a long period of time and
has minimal fluctuations. Considering the problem of asymptomatic PHPT from this perspective, the cost of caring for
these patients is no more than that of an average person
without this disease. If a physician is concerned about lapses

Medical and Surgical Treatment Decisions
In view of the changing patterns in the presentation of PHPT,
it is necessary to devise new criteria that will help select
those patients at risk of developing complications so that
early surgical intervention can be achieved. Unfortunately,
no definitive studies are available to predict the natural
history of this disease in any given patient (2). Based on a
group of patients who did or did not receive operations, the
criteria for surgical intervention in an asymptomatic patient
is given in Table V. Many studies that are involved in
evaluating these patients are not included in the decisionmaking process because these tests lack evidence that they
are predictors of significant morbidity. Parathyroidectomy
is the treatment of choice in patients with symptomatic
hypercalcemia or in those with evidence of target organ

Table V
Utility of Various Tests in Management of PHPT
Test Results Favoring Surgical Intervention*
Serum calcium consistently above 12 mg/dL
Decreased glomerular filtration rate adjusted for age
Decreased bone mineral content adjusted for age, sex, and race
Presence of target organ effects (bone or stone disease)
Tests Not Helpful in Deciding Surgical Intervention
Serum immunoreactive PTH
Nephrogenous cAMP
Tubular reabsorption of phosphate (TmP/GFR)
Urinary calcium excretion
'Even in absence of symptoms
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in follow-up, surgery may be considered even in the absence
of symptoms or signs of PHPT.
No effective pharmaceutical preparation is currently available for the long-term treatment of PHPT (24). Several
medications used in the management of symptomatic
hypercalcemic patients have varying results and are generally ineffective for most patients (25). Although estrogens
have been shown to be beneficial in lowering serum calcium

in patients with PHPT (26), the response is unpredictable in
any given patient. In addition, estrogen dose required to
lower serum calcium may be unacceptably high. In selected
postmenopausal white females in whom surgery is either
contraindicated or not opted by the patient, estrogen
therapy may be considered if serum calcium is consistently
above 12 mg/dL.
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